I received my session agenda for BIO last week. It looks to be a fantastic program this year, with a very global focus.
Keynoting is Michael J. Fox on “Driving the Development and Availability of Novel Therapies” on Monday, May 7. The vendor companies Burrill & Company and Ernst & Young each present their reports Monday and Tuesday respectively.
Across each day, there are a series of fantastic panels on global health. With all of the recent news out of Thailand, I’m looking forward to the Sunday session “Thailand: Investment and Collaboration in Agricultural Development and Medical Innovation.” The description reads, “In support of biotech investment opportunities, Thailand provides excellent infrastructure, hands-on professionals, existing world-class research, government incentives and biodiversity.” I wonder if ‘government incentives’ is a euphemism for ‘violating your patents.’ Strange things happen when you are looking down the barrel of the gun.
In the public relations program track “Too Much? Communicating Drug Costs to the Public & Media” sounds fascinating given the recent criticisms of high drug costs for biotech products.
The global focus should make this a really good meeting.
Keynoting is Michael J. Fox on “Driving the Development and Availability of Novel Therapies” on Monday, May 7. The vendor companies Burrill & Company and Ernst & Young each present their reports Monday and Tuesday respectively.
Across each day, there are a series of fantastic panels on global health. With all of the recent news out of Thailand, I’m looking forward to the Sunday session “Thailand: Investment and Collaboration in Agricultural Development and Medical Innovation.” The description reads, “In support of biotech investment opportunities, Thailand provides excellent infrastructure, hands-on professionals, existing world-class research, government incentives and biodiversity.” I wonder if ‘government incentives’ is a euphemism for ‘violating your patents.’ Strange things happen when you are looking down the barrel of the gun.
In the public relations program track “Too Much? Communicating Drug Costs to the Public & Media” sounds fascinating given the recent criticisms of high drug costs for biotech products.
The global focus should make this a really good meeting.
